Live feed16:05:00·1dPRReleaseBBOT Presents Preclinical Data Demonstrating pan-KRAS Inhibitor BBO-11818 Has Robust Anti-Tumor Activity in KRAS-Mutant Preclinical Models at the AACR Annual Meeting 2026BBOT· BridgeBio Oncology Therapeutics Inc.Health CareOriginal source
